Skip to main content

Parcopa Side Effects

Generic name: carbidopa / levodopa

Medically reviewed by Last updated on Jan 16, 2024.

Note: This document contains side effect information about carbidopa / levodopa. Some dosage forms listed on this page may not apply to the brand name Parcopa.

Applies to carbidopa / levodopa: oral capsule extended release, oral tablet, oral tablet disintegrating, oral tablet extended release.

Serious side effects of Parcopa

Along with its needed effects, carbidopa / levodopa may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.

Check with your doctor immediately if any of the following side effects occur while taking carbidopa / levodopa:

More common

Less common

Incidence not known

Other side effects of Parcopa

Some side effects of carbidopa / levodopa may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects.

Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:

Less common

Incidence not known

For Healthcare Professionals

Applies to carbidopa / levodopa: enteral suspension, oral capsule extended release, oral tablet, oral tablet disintegrating, oral tablet extended release.


The most common adverse reactions reported include nausea, dizziness, headache, insomnia, abnormal dreams, dry mouth, dyskinesia, anxiety, constipation, vomiting, and orthostatic hypotension.[Ref]

Nervous system

Very common (10% or more): Headache (up to 17%), dyskinesia (up to 16.5%), dizziness (up to 12%)

Common (1% to 10%): Confusion, dystonia, on-off phenomena, hypoesthesia, polyneuropathy, tremor, dysgeusia, bradykinesia

Uncommon (0.1% to 1%): Paresthesia, ataxia, gait disturbance, convulsion

Rare (less than 0.1%): Malignant, neuroleptic syndrome

Frequency not reported: Chorea, somnolence, memory impairment, sense of stimulation

Postmarketing reports: Polyneuropathy[Ref]


Very common (10% or more): Anxiety, insomnia, depression (up to 11%)

Common (1% to 10%): Hallucinations, psychosis, abnormal dreams, sleep disorder, agitation, impulsive behavior, sleep attacks

Uncommon (0.1% to 1%): Suicide, dementia, disorientation, euphoric mood, fear

Rare (less than 0.1%): Abnormal thinking

Postmarketing: Suicide attempt, suicidal ideation[Ref]


Very common (10% or more): Nausea (up to 30%), constipation (up to 22%)

Common (1% to 10%): Dry mouth, constipation, vomiting, hiatal hernia, postoperative ileus, diarrhea, dyspepsia, abdominal distension, dysphagia, flatulence, bitter taste

Uncommon (0.1% to 1%): Salivary hypersecretion

Rare (less than 0.1%): Bruxism, saliva discoloration, glossodynia, hiccups, trismus, burning tongue sensation

Frequency not reported: Heartburn[Ref]


Common (1% to 10%): Ischemic events, orthostatic hypotension, peripheral edema, hypertension, syncope, irregular heart rate, hypotension

Uncommon (0.1% to 1%): Palpitations, phlebitis

Frequency not reported: Chest pain, myocardial infarction[Ref]

Cardiovascular ischemic events occurred in 2.4% (7 of 289) patients receiving carbidopa-levodopa extended-release capsules compared to 1.1% (1 of 92) of patients receiving placebo in early Parkinson's disease clinical trials. In advanced Parkinson's disease, 0.7 % (3 of 450) patients experienced cardiovascular ischemic events. These patients had a previous history of ischemic heart disease or risk factors for ischemic heart disease.[Ref]


Common (1% to 10%): Excessive granulation tissue, rash, contact dermatitis, hyperhidrosis, pruritus

Uncommon (0.1% to 1%): Alopecia, erythema, urticaria

Rare (less than 0.1%): Sweat discoloration, angioedema

Postmarketing reports: Henoch-Schonlein purpura[Ref]


Insertion site complication was reported in 57% of patients who received this drug compared with 44% of patients who received a PEG-J tube without receiving treatment. The most common adverse reactions associated with naso-jejunal (NJ) insertion were oropharyngeal pain, abdominal distention, abdominal pain, abdominal discomfort, pain, throat irritation, gastrointestinal injury, esophageal hemorrhage, anxiety, dysphagia, and vomiting. The most common adverse reactions associated with PEG-J insertion included upper abdominal pain, duodenal ulcer, duodenal ulcer hemorrhage, erosive duodenitis, erosive gastritis, gastrointestinal hemorrhage, intussusception, peritonitis, post-operative abscess, and small intestine ulcer.[Ref]

Very common (10% or more): Insertion site complication, incision site erythema (19%), post-operative wound infection

Common (1% to 10%): Incision site cellulitis, post procedural infection, device dislocation, device occlusion

Uncommon (0.1% to 1%): Postoperative abscess, bezoar, ischemic colitis

Postmarketing reports: Gastric perforation, gastrointestinal perforation, small intestinal ischemia, small intestinal perforation[Ref]


Postmarketing reports: Anaphylactic reaction, bullous lesions[Ref]


Common (1% to 10%): Upper respiratory tract infection, atelectasis, dyspnea, aspiration pneumonia, oropharyngeal pain

Uncommon (0.1% to 1%): Dysphonia, hoarseness

Rare (less than 0.1%): Abnormal respiration

Frequency not reported: Bizarre breathing pattern[Ref]


Frequency not reported: Elevated alkaline phosphatases, AST, ALT, LDH, and bilirubin[Ref]


Frequency not reported: Elevated serum urea and creatinine[Ref]


Very common (10% or more): Asthenia, fatigue

Common (1% to 10%): Pyrexia, malaise

Frequency not reported: Hot flashes[Ref]


Common (1% to 10%): Urinary tract infection, urinary incontinence, urinary retention

Uncommon (0.1% to 1%): Urinary frequency

Rare (less than 0.1%): Priapism[Ref]


Common (1% to 10%): Anemia

Uncommon (0.1% to 1%): Leukopenia, thrombocytopenia

Rare (less than 0.1%): Hemolytic anemia

Very rare (less than 0.01%): Agranulocytosis

Frequency not reported: Positive Coombs test, reduced hemoglobin and hematocrit[Ref]


Very common (10% or more): Decreased weight

Common (1% to 10%): Anorexia, increased weight, vitamin B6 deficiency, vitamin B12 deficiency

Frequency not reported: Elevated blood sugar

Postmarketing reports: Folic acid deficiency[Ref]


Common (1% to 10%): Back pain, shoulder pain

Uncommon (0.1% to 1%): Muscle cramps, neck pain

Frequency not reported: Muscle twitching, leg pain[Ref]


Uncommon (0.1% to 1%): Blepharospasm, diplopia, optic ischemic neuropathy, blurred vision

Rare (less than 0.1%): Mydriasis, oculogyric crisis, activation of a latent Horner's syndrome[Ref]


Rare (less than 0.1%): Malignant melanoma[Ref]

Frequently asked questions


1. (2001) "Product Information. Sinemet (carbidopa-levodopa)." DuPont Pharmaceuticals

2. (2001) "Product Information. Sinemet CR (carbidopa-levodopa)." DuPont Pharmaceuticals

3. (2004) "Product Information. Parcopa (carbidopa-levodopa)." Schwarz Pharma

4. Cerner Multum, Inc. "UK Summary of Product Characteristics."

5. Cerner Multum, Inc. "Australian Product Information."

6. (2015) "Product Information. Rytary (carbidopa-levodopa)." Impax Generics

7. (2015) "Product Information. Duopa (carbidopa-levodopa)." AbbVie US LLC

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Some side effects may not be reported. You may report them to the FDA.